# 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions

> **NCT01260948** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Donepezil Hydrochloride
- **DRUG:** Aricept®

## Key facts

- **NCT ID:** NCT01260948
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2011-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260948, "10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01260948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*